The path from innovation to implementation Image: Courtesy of Penn Medicine Magazine The path from innovation to implementation Penn’s infrastructure in both supporting clinical research and forging commercial partnerships smooths the way from idea to approval.
Two Penn faculty elected to the American Philosophical Society Paul Offit, the Maurice R. Hilleman Chair of Vaccinology in the Department of Pediatrics at the Perelman School of Medicine, and director of the Vaccine Education Center at the Children’s Hospital of Philadelphia; and Dorothy E. Roberts, the George A. Weiss University Professor of Law and Sociology and the Raymond Pace and Sadie Tanner Mossell Alexander Professor of Civil Rights. (Images: (Left) Courtesy of the Children’s Hospital of Philadelphia and (right) Sameer A. Khan) Two Penn faculty elected to the American Philosophical Society Paul Offit and Dorothy Roberts have been recognized for extraordinary accomplishments in their fields.
Improved gene editing method could power future cell and gene therapies Image: Courtesy of Penn Medicine News Improved gene editing method could power future cell and gene therapies A new technique based on special cell-penetrating peptides promises advantages over current methods for editing the genomes of primary cells, such as patients’ T cells.
Why Penn research powers many FDA-approved treatments On August 30, 2017, faculty and staff at the Perelman Center for Advanced Medicine gathered for a “flash mob” celebration of the the FDA approval of a Penn Medicine-developed personalized cellular immune therapy. (Image: Courtesy of Penn Medicine News) Why Penn research powers many FDA-approved treatments Since 2017, the FDA approved more than two dozen new therapies with roots at Penn Medicine—almost half of which are first-in-class for their indications.
Philadelphia life sciences jobs being filled more by women than men, study finds Philadelphia Business Journal Philadelphia life sciences jobs being filled more by women than men, study finds Jean Bennett, Katalin Karikó, and Drew Weissman of the Perelman School of Medicine are noted for their advancements in gene therapy and mRNA technology. Moderna, Merck show progress toward cancer vaccines The Wall Street Journal Moderna, Merck show progress toward cancer vaccines Robert Vonderheide of the Perelman School of Medicine says that a combined immunotherapy-vaccine approach could be a game changer for melanoma patients. In what could be a ‘big shift’ for cancer treatment, mRNA vaccine shows promise against melanoma USA Today In what could be a ‘big shift’ for cancer treatment, mRNA vaccine shows promise against melanoma According to Robert Vonderheide of the Perelman School of Medicine, the pandemic proved that mRNA vaccines could be used safely and developed quickly. Novel treatment shows promise against rare cancer in kids Associated Press Novel treatment shows promise against rare cancer in kids Carl June of the Perelman School of Medicine comments on the success of a new study using CAR-T cell therapy to combat tumors in children with a rare kind of cancer. Could the silver lining of the pandemic be pan-vaccines? The Hill Could the silver lining of the pandemic be pan-vaccines? Scott Hensley of the Perelman School of Medicine and colleagues have developed a vaccine that could provide a baseline level of protection against all 20 known flu strains. A potential strategy to improve T cell therapy in solid tumors Image: Courtesy of Penn Medicine News A potential strategy to improve T cell therapy in solid tumors A new Penn Medicine preclinical study finds that a new simultaneous “knockout” of two inflammatory regulators boosted T cell expansion to attach solid tumors. Load More
Moderna, Merck show progress toward cancer vaccines The Wall Street Journal Moderna, Merck show progress toward cancer vaccines Robert Vonderheide of the Perelman School of Medicine says that a combined immunotherapy-vaccine approach could be a game changer for melanoma patients. In what could be a ‘big shift’ for cancer treatment, mRNA vaccine shows promise against melanoma USA Today In what could be a ‘big shift’ for cancer treatment, mRNA vaccine shows promise against melanoma According to Robert Vonderheide of the Perelman School of Medicine, the pandemic proved that mRNA vaccines could be used safely and developed quickly. Novel treatment shows promise against rare cancer in kids Associated Press Novel treatment shows promise against rare cancer in kids Carl June of the Perelman School of Medicine comments on the success of a new study using CAR-T cell therapy to combat tumors in children with a rare kind of cancer. Could the silver lining of the pandemic be pan-vaccines? The Hill Could the silver lining of the pandemic be pan-vaccines? Scott Hensley of the Perelman School of Medicine and colleagues have developed a vaccine that could provide a baseline level of protection against all 20 known flu strains. A potential strategy to improve T cell therapy in solid tumors Image: Courtesy of Penn Medicine News A potential strategy to improve T cell therapy in solid tumors A new Penn Medicine preclinical study finds that a new simultaneous “knockout” of two inflammatory regulators boosted T cell expansion to attach solid tumors. Load More
In what could be a ‘big shift’ for cancer treatment, mRNA vaccine shows promise against melanoma USA Today In what could be a ‘big shift’ for cancer treatment, mRNA vaccine shows promise against melanoma According to Robert Vonderheide of the Perelman School of Medicine, the pandemic proved that mRNA vaccines could be used safely and developed quickly. Novel treatment shows promise against rare cancer in kids Associated Press Novel treatment shows promise against rare cancer in kids Carl June of the Perelman School of Medicine comments on the success of a new study using CAR-T cell therapy to combat tumors in children with a rare kind of cancer. Could the silver lining of the pandemic be pan-vaccines? The Hill Could the silver lining of the pandemic be pan-vaccines? Scott Hensley of the Perelman School of Medicine and colleagues have developed a vaccine that could provide a baseline level of protection against all 20 known flu strains. A potential strategy to improve T cell therapy in solid tumors Image: Courtesy of Penn Medicine News A potential strategy to improve T cell therapy in solid tumors A new Penn Medicine preclinical study finds that a new simultaneous “knockout” of two inflammatory regulators boosted T cell expansion to attach solid tumors. Load More
Novel treatment shows promise against rare cancer in kids Associated Press Novel treatment shows promise against rare cancer in kids Carl June of the Perelman School of Medicine comments on the success of a new study using CAR-T cell therapy to combat tumors in children with a rare kind of cancer. Could the silver lining of the pandemic be pan-vaccines? The Hill Could the silver lining of the pandemic be pan-vaccines? Scott Hensley of the Perelman School of Medicine and colleagues have developed a vaccine that could provide a baseline level of protection against all 20 known flu strains. A potential strategy to improve T cell therapy in solid tumors Image: Courtesy of Penn Medicine News A potential strategy to improve T cell therapy in solid tumors A new Penn Medicine preclinical study finds that a new simultaneous “knockout” of two inflammatory regulators boosted T cell expansion to attach solid tumors. Load More
Could the silver lining of the pandemic be pan-vaccines? The Hill Could the silver lining of the pandemic be pan-vaccines? Scott Hensley of the Perelman School of Medicine and colleagues have developed a vaccine that could provide a baseline level of protection against all 20 known flu strains. A potential strategy to improve T cell therapy in solid tumors Image: Courtesy of Penn Medicine News A potential strategy to improve T cell therapy in solid tumors A new Penn Medicine preclinical study finds that a new simultaneous “knockout” of two inflammatory regulators boosted T cell expansion to attach solid tumors.
A potential strategy to improve T cell therapy in solid tumors Image: Courtesy of Penn Medicine News A potential strategy to improve T cell therapy in solid tumors A new Penn Medicine preclinical study finds that a new simultaneous “knockout” of two inflammatory regulators boosted T cell expansion to attach solid tumors.